Eudesmin

Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities.

Product information

CAS Number: 526-06-7

Molecular Weight: 386.44

Formula: C22H26O6

Synonym:

(-)-Eudesmin; Eudesmine

(-)-Eudesmine

Chemical Name: (1R, 3aS, 4R, 6aS)-1, 4-bis(3, 4-dimethoxyphenyl)-hexahydrofuro[3, 4-c]furan

Smiles: COC1C=CC(=CC=1OC)[C@@H]1OC[C@H]2[C@@H](OC[C@H]21)C1C=C(OC)C(=CC=1)OC

InChiKey: PEUUVVGQIVMSAW-DJDZNOHASA-N

InChi: InChI=1S/C22H26O6/c1-23-17-7-5-13(9-19(17)25-3)21-15-11-28-22(16(15)12-27-21)14-6-8-18(24-2)20(10-14)26-4/h5-10,15-16,21-22H,11-12H2,1-4H3/t15-,16-,21+,22+/m1/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 100 mg/mL (258.77 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥360 days if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Treatment of mesenchymal stem cells (MSCs) with Eudesmin (20, 40, and 80μM) disturbs adipogenesis via suppression of S6K1 signaling pathway. Eudesmin treatment inhibits activation and nuclear translocation of S6K1. S6K1-mediated phosphorylation of H2B at serine 36 (H2BS36p) is reduced upon Eudesmin treatment.

References:

1. Ki Hong Nam, et al. Eudesmin Impairs Adipogenic Differentiation via Inhibition of S6K1 Signaling Pathway. Biochem Biophys Res Commun. 2018 Nov 10;505(4):1148-1153.

Products are for research use only. Not for human use.